1-氨基-4-苯基环己烷羧酸 | 117259-23-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 1-氨基-4-苯基环己烷羧酸
• 英文名称: 1-amino-4-phenylcyclohexane-1-carboxylic acid
• 英文别名: 1-amino-4-phenylcyclohexane carboxylic acid；1-Amino-4-phenyl-cyclohexan-carbonsaeure；1-Azaniumyl-4-phenylcyclohexane-1-carboxylate
• CAS: 117259-23-1
• 化学式: C₁₃H₁₇NO₂
• 分子量: 219.283
• InChiKey: TWAYLYPZRSXEOS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  氯甲酸-9-芴基甲酯 、 1-氨基-4-苯基环己烷羧酸 以 1,4-二氧六环 、 水 为溶剂， 生成 、 1-(9H-fluoren-9-ylmethoxycarbonylamino)-4-phenylcyclohexane-1-carboxylic acid
  参考文献：
  名称：

  Discovery of 1-amino-4-phenylcyclohexane-1-carboxylic acid and its influence on agonist selectivity between human melanocortin-4 and -1 receptors in linear pentapeptides

  摘要：

  Linear pentapeptides (Penta-cis-Apc-DPhe-Arg-Trp-Gly-NH2) containing 1-amino-4-phenylcyclohexane-1-carboxylic acid (cis-Apc) and substituted Apc are potent hMC4R agonists and they are inactive or weakly active in hMC1R, hMC3R, and hMC5R agonist assays. This study, together with our earlier report on 5-BrAtc, demonstrated the importance of replacing His6 with phenyl-containing rigid templates in achieving good hMC4R agonist potency and selectivity against hMC1R in linear pentapeptides.

  DOI：

  10.1016/j.bmcl.2005.08.012
• 作为产物：
  描述：

  8-苯基-1,3-二氮杂螺[4.5]癸烷-2,4-二酮 在 4-二甲氨基吡啶 、 sodium hydroxide 、 三乙胺 作用下， 以 四氢呋喃 、 乙二醇二甲醚 为溶剂， 生成 1-氨基-4-苯基环己烷羧酸
  参考文献：
  名称：

  Discovery of 1-amino-4-phenylcyclohexane-1-carboxylic acid and its influence on agonist selectivity between human melanocortin-4 and -1 receptors in linear pentapeptides

  摘要：

  Linear pentapeptides (Penta-cis-Apc-DPhe-Arg-Trp-Gly-NH2) containing 1-amino-4-phenylcyclohexane-1-carboxylic acid (cis-Apc) and substituted Apc are potent hMC4R agonists and they are inactive or weakly active in hMC1R, hMC3R, and hMC5R agonist assays. This study, together with our earlier report on 5-BrAtc, demonstrated the importance of replacing His6 with phenyl-containing rigid templates in achieving good hMC4R agonist potency and selectivity against hMC1R in linear pentapeptides.

  DOI：

  10.1016/j.bmcl.2005.08.012

文献信息

• Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity
  申请人：——

  公开号：US20010056179A1

  公开（公告）日：2001-12-27

  Peptides of formulae I, II and III selectively activate melanocortin-4 (MC-4) receptor activity. 1

  公式I、II和III的肽选择性地激活黑色素皮质素-4（MC-4）受体活性。
• Selective cyclic peptides with melanocortin-4 receptor (MC4-R) agonist activity
  申请人：——

  公开号：US20020143141A1

  公开（公告）日：2002-10-03

  Peptides cyclized via disulfide or lactam bridges having melanocortin-4 receptor (MC4-R) agonist activity useful for treatment of obesity.

  经过二硫键或内酰胺桥环化的肽具有黑色素皮质激素受体（MC4-R）激动剂活性，适用于治疗肥胖症。
• Selective linear peptides with melanocor tin-4 receptor (MC4-R) agonist activity
  申请人：——

  公开号：US20030229200A1

  公开（公告）日：2003-12-11

  Peptides of formulae I, II and III that selectively activate melanocortin-4 (MC-4) receptor activity. 1

  化学式为I、II和III的多肽，可选择性激活黑色素细胞激素-4（MC-4）受体活性。
• Selective Linear Peptides with Melanocortin-4 Receptor (MC4-R) Agonist Activity
  申请人：Chen Li

  公开号：US20080177036A1

  公开（公告）日：2008-07-24

  Peptides of formulae I, II and III that selectively activate melanocortin-4 (MC-4) receptor activity.

  化学式为I、II和III的肽，可选择性地激活黑色素细胞激素受体-4（MC-4）的活性。
• PHARMACEUTICAL COMPOSITIONS
  申请人：RHYTHM METABOLIC, INC.

  公开号：US20160022764A1

  公开（公告）日：2016-01-28

  The present invention relates to an ionic complex comprising a cationic polypeptide and an anionic excipient selected from: a PEG-carboxylic acid; a fatty acid having 10 or more carbon atoms; an anionic phospholipid; and a combination thereof. The invention also relates to a pharmaceutical composition comprising the ionic complex of the invention and a pharmaceutically acceptable carrier. The cationic polypeptide of the ionic complex has pharmacological activity and the complex can provide a more desirable pharmacokinetic profile for the cationic polypeptide of the complex as compared to the cationic polypeptide alone following administration. As such, the invention also relates to the use of the ionic complex and pharmaceutical composition comprising same to treat a subject suffering from a disease or disorder that is responsive to the cationic polypeptide of the ionic complex.

  本发明涉及一种离子复合物，包括阳离子多肽和阴离子辅料，所述阴离子辅料选自：PEG-羧酸；具有10个或更多碳原子的脂肪酸；阴离子磷脂；以及其组合物。该发明还涉及一种药物组合物，包括本发明的离子复合物和药学上可接受的载体。离子复合物的阳离子多肽具有药理活性，并且与仅使用阳离子多肽相比，复合物可以提供更理想的药代动力学特性。因此，本发明还涉及使用离子复合物和包括其的药物组合物来治疗对离子复合物的阳离子多肽有反应的疾病或障碍的患者。